+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Autoinjectors Market By Type, By Application, By End Use, By Country, Industry Analysis and Forecast, 2020 - 2026

  • PDF Icon

    Report

  • 97 Pages
  • December 2020
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5233775
The Asia Pacific Autoinjectors Market is expected to witness market growth of 19.1% CAGR during the forecast period (2020-2026).

Most of the autoinjectors are single-use, disposable, spring-loaded syringes. The autoinjectors are designed in such a way that it makes them easy to use and are planned for self-administration by patients, or delivered by even untrained personnel. The place of injection mainly depends on the drug-loaded, but it is usually administered into either thigh or buttocks. Auto-injectors are favored over conventional devices because they allow efficient and enhanced drug delivery even in new formulations. The advancement of technology in products are estimated to boost growth.

Market growth is mainly driven by the increasing incidences of targeted therapies, the increasing occurrence of anaphylaxis, growing inclination for self-administration of drugs. Further, the usability benefits, the growing number of governing approvals, and the accessibility of standard versions of autoinjectors, favorable settlements pertaining to the autoinjectors is fuelling the market. In addition, government’s provision as well as technological advancements are likely to turn this market more opportunistic. The patent termination of biologics is also anticipated to deliver growth opportunities for the market.

The growth of the market in the Asia Pacific market is largely due to the large number of patients suffering from chronic allergies and diabetes as well as increasing healthcare expenditure. This in turn has drawn a number of key auto-injector device manufacturers to this region. These companies are showing more presence in the Asia Pacific market via several approaches, including partnering with local pharmaceutical companies and establishing sales offices.

Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Disposable autoinjectors
  • Reusable autoinjectors

By Application
  • Anaphylaxis
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Other Applications

By End Use
  • Hospitals & Clinics
  • Home care settings

By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled
  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.

Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Autoinjectors Market, by Type
1.4.2 Asia Pacific Autoinjectors Market, by Application
1.4.3 Asia Pacific Autoinjectors Market, by End Use
1.4.4 Asia Pacific Autoinjectors Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Geographical Expansions
3.2.4 Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, May - 2020, Nov) Leading Players
Chapter 4. Asia Pacific Autoinjectors Market by Type
4.1 Asia Pacific Disposable autoinjectors Market by Country
4.2 Asia Pacific Reusable autoinjectors Market by Country
Chapter 5. Asia Pacific Autoinjectors Market by Application
5.1 Asia Pacific Anaphylaxis Market by Country
5.2 Asia Pacific Rheumatoid Arthritis Market by Country
5.3 Asia Pacific Multiple Sclerosis Market by Country
5.4 Asia Pacific Other Application Market by Country
Chapter 6. Asia Pacific Autoinjectors Market by End Use
6.1 Asia Pacific Hospitals & Clinics Autoinjectors Market by Country
6.2 Asia Pacific Home care settings Autoinjectors Market by Country
Chapter 7. Asia Pacific Autoinjectors Market by Country
7.1 China Autoinjectors Market
7.1.1 China Autoinjectors Market by Type
7.1.2 China Autoinjectors Market by Application
7.1.3 China Autoinjectors Market by End Use
7.2 Japan Autoinjectors Market
7.2.1 Japan Autoinjectors Market by Type
7.2.2 Japan Autoinjectors Market by Application
7.2.3 Japan Autoinjectors Market by End Use
7.3 India Autoinjectors Market
7.3.1 India Autoinjectors Market by Type
7.3.2 India Autoinjectors Market by Application
7.3.3 India Autoinjectors Market by End Use
7.4 South Korea Autoinjectors Market
7.4.1 South Korea Autoinjectors Market by Type
7.4.2 South Korea Autoinjectors Market by Application
7.4.3 South Korea Autoinjectors Market by End Use
7.5 Singapore Autoinjectors Market
7.5.1 Singapore Autoinjectors Market by Type
7.5.2 Singapore Autoinjectors Market by Application
7.5.3 Singapore Autoinjectors Market by End Use
7.6 Malaysia Autoinjectors Market
7.6.1 Malaysia Autoinjectors Market by Type
7.6.2 Malaysia Autoinjectors Market by Application
7.6.3 Malaysia Autoinjectors Market by End Use
7.7 Rest of Asia Pacific Autoinjectors Market
7.7.1 Rest of Asia Pacific Autoinjectors Market by Type
7.7.2 Rest of Asia Pacific Autoinjectors Market by Application
7.7.3 Rest of Asia Pacific Autoinjectors Market by End Use
Chapter 8. Company Profiles
8.1 Eli Lilly and Company
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Geographical Expansions:
8.2 GlaxoSmithKline PLC (GSK)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.1 Recent strategies and developments:
8.2.1.1 Approvals:
8.3 Merck Group
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.4 Sanofi S.A.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Approvals:
8.4.5.3 Product Launches and Product Expansions:
8.5 Becton, Dickinson and Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.6 Teva Pharmaceutical Industries Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Approvals:
8.7 Amgen, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Research & Development Expense
8.7.4 Recent strategies and developments:
8.7.4.1 Product Launches and Product Expansions:
8.8 Ypsomed AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.9 AbbVie, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Biogen, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:

Companies Mentioned

  • Eli Lilly and Company
  • GlaxoSmithKline PLC (GSK)
  • Merck Group
  • Sanofi S.A.
  • Becton, Dickinson and Company
  • Teva Pharmaceuticals Industries Ltd.
  • Amgen, Inc.
  • Ypsomed AG
  • AbbVie, Inc.
  • Biogen, Inc.

Methodology

Loading
LOADING...